First Time Loading...

BRAIN Biotech AG
XETRA:BNN

Watchlist Manager
BRAIN Biotech AG Logo
BRAIN Biotech AG
XETRA:BNN
Watchlist
Price: 2.81 EUR 0.72% Market Closed
Updated: Apr 25, 2024

Gross Margin
BRAIN Biotech AG

56.1%
Current
56%
Average
23.7%
Industry
Positive for the last year
56.1%
Positive average
56%
Better than average
Better than industry value

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.1%
=
Gross Profit
31m
/
Revenue
55.2m

Gross Margin Across Competitors

Gross Margin Comparison
BRAIN Biotech AG Competitors

Country Company Market Cap Gross
Margin
DE
BRAIN Biotech AG
XETRA:BNN
61.4m EUR
56%
JP
Shin-Etsu Chemical Co Ltd
TSE:4063
12.6T JPY
39%
US
Sherwin-Williams Co
NYSE:SHW
78B USD
47%
US
Ecolab Inc
NYSE:ECL
62.8B USD
40%
CH
Sika AG
SIX:SIKA
41B CHF
54%
CH
Givaudan SA
SIX:GIVN
36.2B CHF
41%
CN
Wanhua Chemical Group Co Ltd
SSE:600309
265.3B CNY
17%
IN
Asian Paints Ltd
NSE:ASIANPAINT
2.7T INR
43%
US
Dupont De Nemours Inc
NYSE:DD
31.5B USD
35%
US
PPG Industries Inc
NYSE:PPG
30.3B USD
42%
CH
DSM-Firmenich AG
AEX:DSFIR
27.2B EUR
25%
BRAIN Biotech AG
XETRA:BNN
Country DE
Market Cap 61.4m EUR
Gross Margin
56%
Shin-Etsu Chemical Co Ltd
TSE:4063
Country JP
Market Cap 12.6T JPY
Gross Margin
39%
Sherwin-Williams Co
NYSE:SHW
Country US
Market Cap 78B USD
Gross Margin
47%
Ecolab Inc
NYSE:ECL
Country US
Market Cap 62.8B USD
Gross Margin
40%
Sika AG
SIX:SIKA
Country CH
Market Cap 41B CHF
Gross Margin
54%
Givaudan SA
SIX:GIVN
Country CH
Market Cap 36.2B CHF
Gross Margin
41%
Wanhua Chemical Group Co Ltd
SSE:600309
Country CN
Market Cap 265.3B CNY
Gross Margin
17%
Asian Paints Ltd
NSE:ASIANPAINT
Country IN
Market Cap 2.7T INR
Gross Margin
43%
Dupont De Nemours Inc
NYSE:DD
Country US
Market Cap 31.5B USD
Gross Margin
35%
PPG Industries Inc
NYSE:PPG
Country US
Market Cap 30.3B USD
Gross Margin
42%
D
DSM-Firmenich AG
AEX:DSFIR
Country CH
Market Cap 27.2B EUR
Gross Margin
25%

Profitability Report

View the profitability report to see the full profitability analysis for BRAIN Biotech AG.

Full Profitability Report

See Also

Summary
BNN intrinsic value, competitors valuation, and company profile.
DCF Valuation
BNN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BNN stock valuation using valuation multiples.
Wall Street Estimates
BNN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BNN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.1%
=
Gross Profit
31m
/
Revenue
55.2m
What is the Gross Margin of BRAIN Biotech AG?

Based on BRAIN Biotech AG's most recent financial statements, the company has Gross Margin of 56.1%.

ALPHA SPREAD
Join more than 131,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.